D
Replimune Group, Inc. REPL
$8.19 $0.212.57% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$7.98
Volume
301,450
Avg Vol (90D)
3,230,131
Market Cap
$658.93M
Dividend & Yield
--
52-Week Range
$2.68 - $14.80
P/E (TTM)
--
EPS (TTM)
-$3.44
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
The Best AI for Picking Stocks, Ranked by Performance
10/22/2025 - MarketBeat
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know
2/12/2026 - Zacks Investment Research
Replimune Group (REPL) Shares Cross Above 200 DMA
2/9/2026 - Market News Video
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
2/8/2026 - Simply Wall St
Replimune Group (REPL, $7.75) entered Uptrend as Momentum indicator ascends above 0 level on Feb 06, 2026
2/7/2026 - Tickeron - Stocks
Replimune Group (NASDAQ:REPL) Price Target Raised to $14.00
2/5/2026 - MarketBeat
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL), Sable Offshore Corp. (SOC), Sarepta Therapeutics, Inc. (SRPT), and Semler Scientific, Inc. (SMLR)
2/5/2026 - Globe Newswire
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Brokerages
2/5/2026 - MarketBeat
Replimune Group (REPL, $7.01) Stochastic Oscillator left the oversold zone on February 04, 2026
2/5/2026 - Tickeron - Stocks
Replimune Group (REPL, $7.01) entered Downtrend as Momentum indicator drops below 0 level on Feb 04, 2026
2/5/2026 - Tickeron - Stocks
Noteworthy Wednesday Option Activity: REPL, LRMR, RRX
2/4/2026 - Stock Options Channel
Wedbush Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price
2/4/2026 - Ticker Report
Wedbush Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price
2/4/2026 - MarketBeat
Replimune Group (REPL) to Release Quarterly Earnings on Wednesday
2/4/2026 - MarketBeat
Replimune Group (REPL, $7.38) RSI Indicator left the oversold zone on February 03, 2026
2/4/2026 - Tickeron - Stocks
Replimune Group (REPL, $7.38) entered Uptrend as Momentum indicator ascends above 0 level on Feb 03, 2026
2/4/2026 - Tickeron - Stocks
Replimune Group (REPL, $7.38) Moving Average Convergence Divergence (MACD) Histogram turned positive on February 3, 2026
2/4/2026 - Tickeron - Stocks
Replimune Group GAAP EPS of -$0.77 beats by $0.01
2/4/2026 - SeekingAlpha.com: All News
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD)
2/4/2026 - TipRanks Financial Blog
Replimune Group Q3 Earnings Summary & Key Takeaways
2/3/2026 - Benzinga
Earnings Summary: Replimune Group Q3
2/3/2026 - Benzinga
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
2/3/2026 - Globe Newswire
Replimune Group (REPL, $6.98) RSI Indicator left the oversold zone on February 02, 2026
2/3/2026 - Tickeron - Stocks
Replimune Group (REPL, $7.03) Moving Average Convergence Divergence (MACD) Histogram turned negative on January 30, 2026
1/31/2026 - Tickeron - Stocks
Replimune Group (REPL, $7.41) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 29, 2026
1/30/2026 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$317.06M
EBIT (TTM)
-$324.22M
Net Income (TTM)
-$314.85M
Balance Sheet
Total Assets (Q)
$333.59M
Total Debt (Q)
$76.35M
Total Liabilities (Q)
$123.05M
Book Value Per Share (Q)
$2.64
Cash Flow
Cash from Operations (TTM)
-$277.91M
Cash from Investing (TTM)
$216.64M
Cash from Financing (TTM)
$10.49M
Net Change in Cash (TTM)
-$49.29M
Filings
Filing Date
Tuesday, February 3, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 18 and 22 (est)
Price History
Loading...
Beta
1.21
7-Day Total Return
17.14%
30-Day Total Return
-15.64%
60-Day Total Return
-6.50%
90-Day Total Return
75.21%
Year to Date Total Return
-7.87%
1-Year Total Return
-42.62%
2-Year Total Return
14.61%
3-Year Total Return
-67.06%
5-Year Total Return
-77.84%
52-week Low
Jul 22, 2025 - $2.68
52-week High
Feb 21, 2025 - $14.80
Valuation
Market Cap
$658.93M - Small Cap
Enterprise Value
$466.14M
Price/Sales (TTM)
--
Price/Book (Q)
3.02
Dividends and Shares
Shares Outstanding
92.19M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.replimune.com
Phone Number
781 222 9600
Address
500 Unicorn Park Drive
Woburn, MA 01801
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic... more
NASDAQ 02/13/2026 11:37AM Eastern Quotes delayed